Skip to main content
Subscribe
Sign in
Menu
Membership
Events
Knowledge Center
About
Register
Search
Sign In
Sign In
Register
Subscribe
Stephen Taub
Latest Articles
Edgar Allen’s High Ground Beats the Market Despite Shunning AI Stocks
Stephen Taub
October 28, 2026
Hedge Funds Anticipate Anthropic IPO
Stephen Taub
October 27, 2026
Macro Investing Continues to Drive Results at David Einhorn’s Value-Oriented Fund
Stephen Taub
October 26, 2026
Hedge Funds Invested in New Unicorns
Stephen Taub
October 21, 2026
For Members Only
Biopharma’s Sickly September
Stephen Taub
October 20, 2026
Behind Maverick’s Profitable Third Quarter
Stephen Taub
October 19, 2026
For Members Only
While Everybody Chases AI, Glenview’s Health Care Stocks Drive Best Results in a Decade
Stephen Taub
October 14, 2026
For Members Only
Josh Resnick’s Hedge Fund Overhauls Top Holdings. Here’s How They Fared.
Stephen Taub
October 13, 2026
Lone Pine’s Reversal of Fortune
Stephen Taub
October 8, 2026
For Members Only
Third Point Returns to Meta and Nvidia
Stephen Taub
October 7, 2026
For Members Only
Light Street, Valiant Surged — But Not Enough to Erase Losses from July and August
Stephen Taub
October 6, 2026
Flight Deck Rebounds and Seligman Tacks on Another Gain
Stephen Taub
October 5, 2026
For Members Only
Greenlight’s Long Book Is Behind September Loss
Stephen Taub
October 1, 2026
Big Name Hedge Funds Miss Kodiak Sciences’ 178 Percent Stock Rise
Stephen Taub
September 30, 2026
Coatue Becomes Hedge Funds’ Most Active VC Investor
Stephen Taub
September 29, 2026
Biopharma Continues to Buoy the IPO Market
Stephen Taub
September 28, 2026
For Members Only
Seligman Cuts AI Exposure, Preserving a Nearly 40 Percent Gain
Stephen Taub
September 24, 2026
For Members Only
AI Drug Discovery Reaches the IPO Market
Stephen Taub
September 23, 2026
More Articles